Congenica’s Sapientia selected by Hospital Pediátrico de Coimbra for Portugal’s In2Genome Genetic Disease Diagnosis Project

Cambridge, UK, September 06, 2017 Congenica, a global provider of clinical genomics interpretation software, today announced a new customer partnership with the Coimbra Paediatric Hospital (CPH), a leading paediatric hospital in Portugal and part of the Coimbra Hospital and University Centre (CHUC). Through this partnership, the hospital has licensed Congenica’s Sapientia™ software platform to perform analysis of whole-exome sequencing data and... Read more

New Study Confirms High Technical Comparability of Different BRAHMS PCT Assays at all Clinical Cut-offs for Various Clinical Settings

New Study Confirms High Technical Comparability of Different BRAHMS PCT Assays at all Clinical Cut-offs for Various Clinical Settings Analysis shows that high quality BRAHMS PCT (procalcitonin) assays are reliable tools to assist in the safe management of patients with suspected bacterial infection and sepsis HENNIGSDORF, Germany, Sept. 5, 2017 /PRNewswire/ — A new study, recently... Read more

Bristol-Myers Squibb and QIAGEN Sign Agreement for Use of NGS Technology to Develop Gene Expression Profiles for Immuno-Oncology Therapies

NEW YORK and HILDEN, Germany, (June 3, 2017) – Bristol-Myers Squibb Company (NYSE: BMY) and QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) have signed an agreement to explore the use of next-generation sequencing (NGS) technology to develop gene expression profiles (GEPs) as predictive or prognostic tools for use with Bristol-Myers Squibb novel immuno-oncology (I-O) therapies... Read more

Seegene accelerates ‘Project 100’ by securing 30 co-development partners

2017.08.31 Seoul, Korea, 2017/08/31 – Seegene, the world’s leading developer of multiplex molecular technologies and assays, announced that it has recently signed collaborative contracts with 30 general hospitals and reference laboratories across 15 nations for the co-development of ‘Project 100’ products. Contracting parties are mostly the largest commercial labs in the country, university hospitals, and... Read more

Edico Genome Launches DRAGEN On DNAnexus’ Platform

SAN DIEGO, Aug. 30, 2017 /PRNewswire/ — Edico Genome and DNAnexus, Inc. today announced the availability of Edico Genome’s DRAGEN™ on DNAnexus’ genome informatics and data management platform. Through this integration, new and existing DNAnexus customers will be able to utilize DRAGEN’s ultra-rapid Genome Pipeline, significantly reducing costs and turnaround time while enhancing accuracy. DNAnexus provides a global network for sharing... Read more

Illumina and Telegraph Hill Partners Launch Verogen, Inc. to Drive Adoption of Next-Generation Sequencing in the Global Forensic Genomics Market

SAN DIEGO–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ: ILMN) today announced plans with Telegraph Hill Partners (THP), a San Francisco-based venture capital and growth equity firm, to establish Verogen, Inc. The independent new company has certain exclusive rights to provide Illumina’s forensic sequencing technology to forensic customers, including for criminal casework and other human and nonhuman forensic applications.... Read more

BioXp™ Genomic Workstation Makes European Debut at VIB Research Institute in Belgium

SGI-DNA’s benchtop automated DNA printer to accelerate genomic research as part of VIB’s Technology Watch Initiative FLANDERS, BELGIUM AND SAN DIEGO— August 22, 2017 — SGI-DNA Inc., a Synthetic Genomics Inc. (SGI) company, and VIB, a Belgian life science research institute, today announced that VIB will become the first institute in Europe to integrate the BioXp™... Read more

Unchained Labs gets its quant on, launches Lunatic!

August 21, 2017 – Pleasanton, CA – Unchained Labs, the life sciences company that’s all about getting biologics researchers the right tool for the job, launched Lunatic today at the Bioprocessing Summit conference in Boston. Lunatic, a.k.a. The Concentration Liberator, makes batch quantification of protein, DNA and RNA a reality for biologics and genomics researchers.... Read more

Xylem to participate in the Seaport Global Chicago Industrials & Coatings Conference

RYE BROOK, N.Y.–(BUSINESS WIRE)–Aug. 21, 2017– Xylem Inc. (NYSE:XYL), a leading global water technology company dedicated to solving the world’s most challenging water issues, announced today that Matthew Latino, Xylem’s Manager of Investor Relations, will participate in small group meetings at the Seaport Global Chicago Industrials & Coatings Conference at the JW Marriott Chicago on... Read more

Fluidigm Licenses CFTR Next-Generation Sequencing Assay From Baylor Genetics for Use With the Juno System

SOUTH SAN FRANCISCO, Calif., Aug. 17, 2017 (GLOBE NEWSWIRE) — Fluidigm Corporation (NASDAQ:FLDM) and Baylor Genetics today announced that they have entered into a licensing agreement to offer a next-generation sequencing (NGS) library prep assay that enables efficient sequencing of the CFTR (cystic fibrosis transmembrane conductance regulator) gene. Under the agreement, Fluidigm obtains the rights to commercialize the CFTR library prep... Read more